- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | Stifel bestätigt Kaufempfehlung für Rapid Micro Biosystems und hält an Kursziel von 8 US-Dollar fest | 17 | Investing.com Deutsch | ||
| RAPID MICRO BIOSYSTEMS Aktie jetzt für 0€ handeln | |||||
| 13.08. | Stifel reiterates Buy rating on Rapid Micro Biosystems stock, maintains $8 target | 2 | Investing.com | ||
| 12.08. | Rapid Micro Biosystems reaffirms $32M revenue guidance for 2025 as recurring revenue climbs 15% | 1 | Seeking Alpha | ||
| 12.08. | Rapid Micro Biosystems secures $45 million term loan facility | 1 | Investing.com | ||
| 12.08. | Rapid Micro Biosystems GAAP EPS of -$0.27, revenue of $7.3M | 1 | Seeking Alpha | ||
| 12.08. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results | 603 | GlobeNewswire (Europe) | Reports second quarter 2025 total revenue of $7.3 million, representing 10% growth compared to the second quarter of 2024. Second quarter 2025 recurring revenue increased 15% compared to the second... ► Artikel lesen | |
| 12.08. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc. | 605 | GlobeNewswire (Europe) | $20 million drawn down at closing, with access to up to an additional $25 million Strengthens Company's financial position and reinforces ability to achieve positive cash flow LEXINGTON, Mass.,... ► Artikel lesen | |
| 12.08. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.08. | A Look Ahead: Rapid Micro Biosystems' Earnings Forecast | 2 | Benzinga.com | ||
| 31.07. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Announce Second Quarter 2025 Financial Results on August 12, 2025 | 2 | GlobeNewswire (USA) | ||
| 28.07. | Lake Street initiates Rapid Micro Biosystems stock with Buy rating on MQC growth | 6 | Investing.com | ||
| 28.07. | Automatisierte Qualitätskontrolle als Wachstumstreiber: Lake Street stuft Rapid Micro Biosystems mit "Buy" ein | 2 | Investing.com Deutsch | ||
| 17.06. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.06. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 179 | GlobeNewswire (Europe) | LEXINGTON, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation... ► Artikel lesen | |
| 27.05. | Rapid Micro Biosystems appoints new board member | 1 | Investing.com | ||
| 27.05. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 23.05. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.05. | RAPID MICRO BIOSYSTEMS, INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 09.05. | Rapid Micro Biosystems reports Q1 results | 2 | Seeking Alpha | ||
| 09.05. | RAPID MICRO BIOSYSTEMS, INC. Q1 Loss Decreases, Beats Estimates | 1 | RTTNews |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ENLIVEN THERAPEUTICS | 18,960 | -4,84 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
| QIAGEN | 39,005 | +0,26 % | QIAGEN N.V.: QIAGEN erhält europäische CE-IVDR-Zertifizierung für das gesamte QIAstat-Dx-Portfolio | Komplettes Portfolio an QIAstat-Dx-Panels ab jetzt CE-IVDR-zertifiziert und damit für den Einsatz in der klinischen syndromischen Testung zugelassen ein klares Bekenntnis zu Diagnostik auf höchstem... ► Artikel lesen | |
| EVOTEC | 6,272 | -0,32 % | Kurs von Evotec steigt etwas (5,966 €) | Im Plus liegt zur Stunde die Aktie von Evotec . Das Wertpapier notiert derzeit bei 5,97 Euro. Im deutschen Wertpapierhandel hat sich heute die Aktie von Evotec zwischenzeitlich um 2,54 Prozent verteuert.... ► Artikel lesen | |
| HUMACYTE | 1,860 | +3,91 % | Humacyte Plans To File IND For Coronary Tissue Engineered Vessel In Q4 | ||
| RECURSION PHARMACEUTICALS | 4,910 | -0,41 % | Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances | ||
| NUVALENT | 76,64 | -5,34 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| 89BIO | 14,860 | -0,67 % | Milliarden-Pharma-Übernahme: Roche kauft sich in Biotech-Milliardenmarkt ein - 89bio im Fokus | © Foto: SOPA Images - Sipa USARoche kauft das US-amerikanische Biotech-Unternehmen 89bio für bis zu 3,5 Milliarden US-Dollar. Im Fokus steht ein Hoffnungsträger gegen die Fettleberkrankheit MASH, ein... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 6,200 | -2,21 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results | CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's disease BCMA-directed bispecific T cell engager velinotamig... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 41,090 | -1,72 % | Roth/MKM initiates Avidity Biosciences stock with Buy rating on platform potential | ||
| SUMMIT THERAPEUTICS | 18,860 | -1,92 % | Summit Therapeutics stock rating reiterated at Buy by H.C. Wainwright | ||
| ADMA BIOLOGICS | 15,910 | -1,55 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 49,130 | -3,97 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses | ||
| APOGEE THERAPEUTICS | 36,450 | -5,15 % | Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 ... | SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 55,00 | +1,78 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 39,300 | -1,43 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen |
RAPID MICRO BIOSYSTEMS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,130 (+4,04 %) liegt der Kurs bei 3,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPID MICRO BIOSYSTEMS INC finden Sie auf Wallstreet Online.